Xilio Therapeutics, Inc.
Business
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to selectively activate within the tumor microenvironment to minimize systemic toxicity. The company's proprietary masking technology enables development of multiple therapeutic modalities including bispecific antibodies, masked T cell engagers, cytokines, and checkpoint inhibitors targeting validated oncology indications. Xilio is advancing programs through preclinical and clinical stages, including partnerships with AbbVie and Gilead, with lead candidates targeting PD-1/IL-2, PSMA, STEAP1, CLDN18.2, IL-12, and CTLA-4.
Summary from 10-K filed 2026-03-23
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | 44 | 6 | — | — | — | |
| Research and development | 56 | 41 | 52 | 59 | 51 | |
| General and administrative | 30 | 25 | 27 | 30 | 24 | |
| Restructuring | — | 937,000 | — | — | — | |
| Total operating expenses | 86 | 67 | 79 | 89 | 75 | |
| Loss from operations | −42 | −61 | −79 | −89 | −75 | |
| Change in fair value of common stock warrant liabilities | 6 | — | — | — | — | |
| Other income, net | 1 | 2 | 3 | 927,000 | −756,000 | |
| Total other income, net | 7 | 2 | 3 | 927,000 | −756,000 | |
| Net loss and comprehensive loss | −35 | −58 | −76 | −88 | −76 | |
| Net loss per share, basic (in dollars per share) | −4.19 | −15.24 | −2.78 | −3.22 | −13.52 | |
| Net loss per share, diluted (in dollars per share) | −4.19 | −15.24 | −2.78 | −3.22 | −13.52 | |
| Weighted average common shares outstanding, basic (in shares) | 8 | 4 | 27 | 27 | 6 | |
| Weighted average common shares outstanding, diluted (in shares) | 8 | 4 | 27 | 27 | 6 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 138 | 55 | 45 | 120 | 198 | |
| Collaboration and license agreement receivable | 5 | — | — | — | — | |
| Prepaid expenses and other current assets | 2 | 5 | 3 | 4 | 4 | |
| Total current assets | 145 | 60 | 48 | 124 | 203 | |
| Restricted cash | 2 | 2 | 2 | 2 | 2 | |
| Property and equipment, net | 4 | 4 | 6 | 7 | 8 | |
| Operating lease right-of-use asset | 4 | 5 | 5 | 6 | 6 | |
| Total assets | 155 | 71 | 61 | 139 | 218 | |
| Accounts payable | 3 | 3 | 1 | 3 | 3 | |
| Accrued expenses | 12 | 10 | 10 | 10 | 9 | |
| Deferred revenue, current portion | 40 | 14 | — | — | — | |
| Operating lease liability, current portion | 1 | 1 | 1 | 918,000 | 801,000 | |
| Total current liabilities | 56 | 27 | 16 | 21 | 13 | |
| Deferred revenue, net of current portion | 21 | 19 | — | — | — | |
| Operating lease liability, net of current portion | 6 | 7 | 8 | 9 | 10 | |
| Common stock warrant liabilities | 30 | — | — | — | — | |
| Liabilities to issue common stock | 7 | — | — | — | — | |
| Total liabilities | 119 | 53 | 24 | 34 | 33 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding | — | — | — | — | — | |
| Additional paid-in capital | 454 | 401 | 362 | 355 | 346 | |
| Accumulated deficit | −419 | −384 | −326 | −249 | −161 | |
| Total stockholders' equity | 35 | 18 | 37 | 106 | 185 | |
| Total liabilities and stockholders' equity | 155 | 71 | 61 | 139 | 218 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −35 | −58 | −76 | −88 | −76 | |
| Depreciation and amortization | 2 | 2 | 2 | 2 | 1 | |
| Stock-based compensation expense | 7 | 6 | 7 | 8 | 5 | |
| Issuance costs allocated to common stock warrant liabilities | 2 | — | — | — | — | |
| Loss on disposal of property and equipment | — | 3,000 | 3,000 | 1,000 | 19,000 | |
| Collaboration and license agreement receivable | −5 | — | — | — | — | |
| Prepaid and other assets | 3 | −981,000 | 688,000 | 344,000 | −3 | |
| Accounts payable | 152,000 | 2 | −2 | 485,000 | −3 | |
| Accrued expenses and other liabilities | −979,000 | −2 | 175,000 | 2 | −6 | |
| Deferred revenue | 28 | 33 | — | — | — | |
| Net cash used in operating activities | −5 | −18 | −69 | −76 | −81 | |
| Purchases of property and equipment | −518,000 | −36,000 | −486,000 | −2 | −1 | |
| Net cash used in investing activities | −518,000 | −36,000 | −486,000 | −2 | −1 | |
| Proceeds from issuance of prefunded warrants and common stock warrants in connection with a follow-on offering, net of issuance costs | 47 | — | — | — | — | |
| Proceeds from the issuance of common stock, prefunded warrants and liabilities to issue common stock in connection with the exercise of Series B warrants, net of issuance costs | 36 | — | — | — | — | |
| Proceeds from issuance of common stock under employee stock purchase plan | 76,000 | 68,000 | 194,000 | — | — | |
| Proceeds from exercise of stock options | 10,000 | 5,000 | 8,000 | 16,000 | 283,000 | |
| Repayments of debt principal | — | −3 | −7 | — | −1 | |
| Payments of finance lease | — | −49,000 | −85,000 | −85,000 | −85,000 | |
| Net cash provided by financing activities | 88 | 29 | −7 | −69,000 | 261 | |
| Increase in cash, cash equivalents and restricted cash | 82 | 11 | −76 | −78 | 179 | |
| Cash paid for interest | — | 62,000 | 573,000 | 555,000 | 492,000 | |
| Transfer of finance lease asset to property and equipment | — | 85,000 | — | — | — | |
| Capital expenditures included in accounts payable or accrued expenses | 443,000 | — | — | 19,000 | 539,000 | |
| Issuance costs included in accounts payable or accrued expenses | 2 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Xilio Therapeutics, Inc.'s CIK number?
Xilio Therapeutics, Inc.'s SEC CIK number is 0001840233 (1840233). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Xilio Therapeutics, Inc.'s SEC filings?
All of Xilio Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Xilio Therapeutics, Inc. last report earnings?
Xilio Therapeutics, Inc. (XLO) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218194). This is Xilio Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Xilio Therapeutics, Inc.'s most recent earnings 8-K?
Xilio Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218194. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Xilio Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →